Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3

Journal of General Virology

Volumn 87, Issue 1, 2006, Pages 1-10

  Yu, Hong ^a   Huang, Hui ^b   Xiang, Jim ^b   Babiuk, Lorne A ^a   van Drunen Littel van den Hurk, Sylvia ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Research Unit   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; NONSTRUCTURAL PROTEIN 3; VIRUS PROTEIN; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HEPATITIS C VIRUS; IMMUNITY; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; VACCINIA; VACCINIA VIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT;

ANIMALS; DENDRITIC CELLS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; MICE; OLIGODEOXYRIBONUCLEOTIDES; VACCINIA VIRUS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

ANIMALIA; HEPATITIS C VIRUS; VACCINIA VIRUS;

EID: 30344446364     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81423-0     Document Type: Article

References (62)

1. Akira, S., Takeda, K. & Kaisho, T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2, 675-680.
2. Ardavin, C., Amigorena, S. & Reise Sousa, C. (2004). Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20, 17-23.
3. Auffermann-Gretzinger, S., Keeffe, E. B. & Levy, S. (2001). Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97, 3171-3176.
4. Baca-Estrada, M. E., Snider, M., Tikoo, S. K., Harland, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (1996). Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9, 11-22.
5. Banchereau, J., Schuler-Thurner, B., Palucka, A. K. & Schuler, G. (2001). Dendritic cells as vectors for therapy. Cell 106, 271-274.
6. Berberich, C., Ramirez-Pineda, J. R., Hambrecht, C., Alber, G., Skeiky, Y. A. & Moll, H. (2003). Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170, 3171-3179.
7. Berger, T. G. & Schultz, E. S. (2003). Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 276, 163-197.
8. Brown, K., Gao, W., Alber, S., Trichel, A., Murphey-Corb, M., Watkins, S. C., Gambotto, A. & Barratt-Boyes, S. M. (2003). Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 171, 6875-6882.
9. Cerundolo, V., Hermans, I. F. & Salio, M. (2004). Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5, 7-10.
10. Chen, M., Sallberg, M., Sonnerborg, A., Weiland, O., Mattsson, L., Jin, L., Birkett, A., Peterson, D. & Milich, D. R. (1999). Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116, 135-143.
11. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870-876.
12. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71, 6011-6019.
13. d'Ostiani, C. F., Del Sero, G., Bacci, A., Montagnoli, C., Spreca, A., Mencacci, A., Ricciardi-Castagnoli, P. & Romani, L. (2000). Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med 191, 1661-1674.
14. Esser, M. T., Marchese, R. D., Kierstead, L. S., Tussey, L. G., Wang, F., Chirmule, N. & Washabaugh, M. W. (2003). Memory T cells and vaccines. Vaccine 21, 419-430.
15. Fried, M. W., Shiffman, M. L., Reddy, K. R. & 11 other authors (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
16. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M. & Rice, C. M. (1993). Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67, 1385-1395.
17. Harandi, A. M., Eriksson, K. & Holmgren, J. (2003). A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 77, 953-962.
18. Ioannou, X. P., Griebel, P., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2002). The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76, 9002-9010.
19. Iwasaki, A. & Medzhitov, R. (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5, 987-995.
20. Jiao, X., Wang, R. Y., Feng, Z., Alter, H. J. & Shih, J. W. (2003). Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37, 452-460.
21. Jin, L. & Peterson, D. L. (1995). Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 323, 47-53.
22. Kaisho, T. & Akira, S. (2003). Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 3, 373-385.
23. Larsson, M., Babcock, E., Grakoui, A., Shoukry, N., Lauer, G., Rice, C., Walker, C. & Bhardwaj, N. (2004). Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 78, 6151-6161.
24. Lasarte, J. J., Garcia-Granero, M., Lopez, A., Casares, N., Garcia, N., Civeira, M. P., Borras-Cuesta, F. & Prieto, J. (1998). Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 28, 815-822.
25. Lewis, P. J., van Drunen Littel-van den, H. & Babiuk, L. A. (1999). Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73, 10214-10223.
26. Liu, Y., Chiriva-Internati, M., Grizzi, F., Salati, E., Roman, J. J., Lim, S. & Hermonat, P. L. (2001). Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 8, 948-957.
27. Lonsdorf, A. S., Kuekrek, H., Stern, B. V., Boehm, B. O., Lehmann, P. V. & Tary-Lehmann, M. (2003). Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171, 3941-3946.
28. Ludewig, B. (2003). Dendritic cell vaccination and viral infection - animal models. Curr Top Microbiol Immunol 276, 199-214.
29. Lutz, M. B., Kukutsch, N., Ogilvie, A. L., Rossner, S., Koch, F., Romani, N. & Schuler, G. (1999). An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223, 77-92.
30. Manns, M. P., McHutchison, J. G., Gordon, S. C. & 7 other authors (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
31. Matsui, M., Moriya, O., Abdel-Aziz, N., Matsuura, Y., Miyamura, T. & Akatsuka, T. (2002). Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21, 211-220.
32. Moll, H. & Berberich, C. (2001a). Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis. Immunobiology 204, 659-666.
33. Moll, H. & Berberich, C. (2001b). Dendritic cells as vectors for vaccination against infectious diseases. Int J Med Microbiol 291, 323-329.
34. Moriya, O., Matsui, M., Osorio, M., Miyazawa, H., Rice, C. M., Feinstone, S. M., Leppla, S. H., Keith, J. M. & Akatsuka, T. (2001). Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20, 789-796.
35. Mozdzanowska, K., Maiese, K. & Gerhard, W. (2000). Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J Immunol 164, 2635-2643.
36. Murata, K., Lechmann, M., Qiao, M., Gunji, T., Alter, H. J. & Liang, T. J. (2003). Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 100, 6753-6758.
37. Neumann-Haefelin, C., Blum, H. E., Chisari, F. V. & Thimme, R. (2005). T cell response in hepatitis C virus infection. J Clin Virol 32, 75-85.
38. Nieda, M., Tomiyama, M. & Egawa, K. (2003). Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy. Hum Cell 16, 199-204.
39. Nonn, M., Schinz, M., Zumbach, K., Pawlita, M., Schneider, A., Durst, M. & Kaufmann, A. M. (2003). Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 129, 511-520.
40. O'Sullivan, B. & Thomas, R. (2003). CD40 and dendritic cell function. Crit Rev Immunol 23, 83-107.
41. Oumouna, M., Mapletoft, J. W., Karvonen, B. C., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2005). Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79, 2024-2032.
42. Pancholi, P., Perkus, M., Tricoche, N., Liu, Q. & Prince, A. M. (2003). DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77, 382-390.
43. Pawlotsky, J. M. (2003). Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7, 45-66.
44. Pouniotis, D. S., Proudfoot, O., Bogdanoska, V., Apostolopoulos, V., Fifis, T. & Plebanski, M. (2004). Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun 72, 5331-5339.
45. Pulendran, B. (2004). Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199, 227-250.
46. Ramirez-Pineda, J. R., Frohlich, A., Berberich, C. & Moll, H. (2004). Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172, 6281-6289.
47. Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A. M., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2001). CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 11, 333-340.
48. Rao, M., Matyas, G. R., Vancott, T. C., Birx, D. L. & Alving, C. R. (2004). Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein. Immunol Cell Biol 82, 523-530.
49. Rehermann, B. & Chisari, F. V. (2000). Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242, 299-325.
50. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. (1999). Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1, 362-368.
51. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182, 389-400.
52. Samani, T. D., Jolles, B. & Laigle, A. (2001). Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev 11, 129-136.
53. + lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73, 5402-5410.
54. + T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 76, 5062-5070.
55. Sarobe, P., Lasarte, J. J., Zabaleta, A., Arribillaga, L., Arina, A., Melero, I., Borras-Cuesta, F. & Prieto, J. (2003). Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol 77, 10862-10871.
56. Simmonds, P. (1999). Viral heterogeneity of the hepatitis C virus. J Hepatol 31, S54-S60.
57. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J. L., Manns, M. P. & Rehermann, B. (2000). Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6, 578-582.
58. van den Broeke, L. T., Daschbach, E., Thomas, E. K., Andringa, G. & Berzofsky, J. A. (2003). Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171, 5842-5852.
59. Walsh, S. R., Bhardwaj, N. & Gandhil, R. T. (2003). Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Curr HIV Res 1, 205-216.
60. Weeratna, R. D., McCluskie, M. J., Xu, Y. & Davis, H. L. (2000). CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18, 1755-1762.
61. WHO (1999). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6, 35-47.
62. Yu, H., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. (2004). Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 85, 1533-1543.